Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2000 1
2001 1
2003 1
2004 1
2005 1
2006 1
2011 2
2012 4
2013 2
2014 3
2015 2
2016 1
2017 1
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

17 results

Results by year

Filters applied: . Clear all
Page 1
Showing results for renal haluska
Your search for Renát Haluška retrieved no results
Interferon in oncological practice: review of interferon biology, clinical applications, and toxicities.
Jonasch E, Haluska FG. Jonasch E, et al. Oncologist. 2001;6(1):34-55. doi: 10.1634/theoncologist.6-1-34. Oncologist. 2001. PMID: 11161227 Free article. Review.
It then reviews the most common side effects seen in patients treated with IFN, and makes recommendations for the management of IFN-induced toxicity. The major oncological indications for IFN include melanoma, renal cell carcinoma, AIDS-related Kaposi's sarcoma, follicular …
It then reviews the most common side effects seen in patients treated with IFN, and makes recommendations for the management of IFN-induced …
Free fatty acids are associated with obesity, insulin resistance, and atherosclerosis in renal transplant recipients.
Armstrong KA, Hiremagalur B, Haluska BA, Campbell SB, Hawley CM, Marks L, Prins J, Johnson DW, Isbel NM. Armstrong KA, et al. Transplantation. 2005 Oct 15;80(7):937-44. doi: 10.1097/01.tp.0000173792.53561.b6. Transplantation. 2005. PMID: 16249742
BACKGROUND: Insulin resistance (IR) may be implicated in the pathogenesis of atherosclerosis in renal transplant recipients (RTRs) and be contributed to, in part, by free fatty acids (FFAs), produced in excess in centrally obese individuals. ...
BACKGROUND: Insulin resistance (IR) may be implicated in the pathogenesis of atherosclerosis in renal transplant recipients (RTRs) an …
Carvedilol and Cardiac Biomarkers in Dialysis Patients: Secondary Analysis of a Randomized Controlled Trial.
Roberts MA, Darssan D, Badve SV, Carroll RP, Fahim MA, Haluska BA, Hawley CM, Isbel NM, Marshall MR, Pascoe EM, Pedagogos E, Pilmore HL, Snelling P, Stanton T, Tan KS, Tonkin AM, Vergara LA, Ierino FL. Roberts MA, et al. Kidney Blood Press Res. 2017;42(6):1033-1044. doi: 10.1159/000485589. Epub 2017 Dec 4. Kidney Blood Press Res. 2017. PMID: 29197871 Free article. Clinical Trial.
Phase I study of temsirolimus in combination with EKB-569 in patients with advanced solid tumors.
Bryce AH, Rao R, Sarkaria J, Reid JM, Qi Y, Qin R, James CD, Jenkins RB, Boni J, Erlichman C, Haluska P. Bryce AH, et al. Invest New Drugs. 2012 Oct;30(5):1934-41. doi: 10.1007/s10637-011-9742-1. Epub 2011 Sep 1. Invest New Drugs. 2012. PMID: 21881915 Free PMC article. Clinical Trial.
Further investigations of this targeting strategy may be attractive in renal cell carcinoma, non-small cell lung cancer, alveolar sarcoma, and carcinoid tumor....
Further investigations of this targeting strategy may be attractive in renal cell carcinoma, non-small cell lung cancer, alveolar sar …
Adjuvant high-dose interferon alfa-2b in patients with high-risk melanoma.
Jonasch E, Kumar UN, Linette GP, Hodi FS, Soiffer RJ, Ryan BF, Sober AJ, Mihm MC, Tsao H, Langley RG, Cosimi BA, Gadd MA, Tanabe KK, Souba W, Haynes HA, Barnhill R, Osteen R, Haluska FG. Jonasch E, et al. Cancer J. 2000 May-Jun;6(3):139-45. Cancer J. 2000. PMID: 10882328 Clinical Trial.
Hepatotoxicity was evident in 39 (97.5%) patients, and 26 (65%) experienced grade 3 to 4 hepatotoxicity. Three patients (7.5%) experienced mild renal toxicity. At a median follow-up of 27 months from initiation of therapy, there have been 19 relapses (47.5% disease-free su …
Hepatotoxicity was evident in 39 (97.5%) patients, and 26 (65%) experienced grade 3 to 4 hepatotoxicity. Three patients (7.5%) experienced m …
17 results